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Gene expression profiling 
UK 
A B S T R A C T   
Social scientific work has considered the promise of genomic medicine to transform healthcare by personalising 
treatment. However, little qualitative research attends to already well-established molecular techniques in 
routine care. In this article we consider women’s experiences of routine breast cancer diagnosis in the UK NHS. 
We attend to patient accounts of the techniques used to subtype breast cancer and guide individual treatment. 
We introduce the concept of ‘diagnostic layering’ to make sense of how the range of clinical techniques used to 
classify breast cancer shape patient experiences of diagnosis. The process of diagnostic layering, whereby various 
levels of diagnostic information are received by patients over time, can render diagnosis as incomplete and 
subject to change. In the example of early breast cancer, progressive layers of diagnostic information are closely 
tied to chemotherapy recommendations. In recent years a genomic test, gene expression profiling, has become 
introduced into routine care. Because gene expression profiling could indicate a treatment recommendation 
where standard tools had failed, the technique could represent a ‘final layer’ of diagnosis for some patients. 
However, the test could also invalidate previous understandings of the cancer, require additional interpretation 
and further prolong the diagnostic process. This research contributes to the sociology of diagnosis by outlining 
how practices of cancer subtyping shape patient experiences of breast cancer. We add to social scientific work 
attending to the complexities of molecular and genomic techniques by considering the blurring of diagnostic and 
therapeutic activities from a patient perspective.   
1. Introduction 
Genomic medicine, which draws on DNA sequencing technology to 
predict disease and ‘personalise’ treatment, is often represented as 
poised to transform the delivery of healthcare (Samuel and Farsides, 
2017; Tutton, 2014). However, social scientists and historians have 
traced how wider practices of molecular medicine, of which genomics is 
a part, have slowly been reconfiguring oncology as a specialism since the 
mid-20th century. This has entailed and provoked the embedding of 
research within clinical practice (Keating and Cambrosio, 2012), re-
definitions of professional roles (Bourret et al., 2011), and has reshaped 
understandings of cancer itself (Bell, 2013). Alongside attention to the 
role of hormones and single genes in cancer, the identification of tumour 
markers has led to the development of ‘targeted’ therapies. This 
scientific and clinical work is entwined with practices of classification as 
cancers become divided into distinct subtypes, in some cases according 
to whether or not they respond to particular therapies (Keating et al., 
2016). 
The success of molecular approaches has been particularly apparent 
in breast cancer. Since the 1990s three cellular receptors, Estrogen (ER), 
Progesterone (PR) and human epidermal growth factor (HER2) have 
been used to classify breast cancer into subtypes. The development of 
hormone treatments and a targeted therapy, Herceptin, has led to 
defined treatment pathways for individual patients where they test 
positively for ER, PR and HER2 status (Keating et al., 2016). Molecular 
subtyping has developed rapidly alongside newer genomic techniques. 
As a consequence, breast cancer is becoming increasingly heterogeneous 
as it is further divided into categories of ‘basal-like’ and ‘luminal’ 
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cancers, and according to known single gene markers such as BRCA1/2 
(ibid). Indeed, a recent article in Nature’s Breast Cancer journal suggests 
that this (ongoing) fragmentation demands that breast cancers be 
considered as rare diseases (Bartlett and Parelukar, 2017). 
Reflective of its heterogeneity, in the UK today a diagnosis of breast 
cancer is multifaceted, informed by factors including the presentation of 
symptoms, clinical imaging and laboratory analysis of tumour tissue. 
Pathology examinations occur at several time points, following one or 
more biopsies and surgeries to remove the cancerous and surrounding 
tissue. Alongside histological laboratory work to establish characteris-
tics such as the tumour’s size and whether it has spread to the lymph 
nodes (LN), the examination of the ER, PR and HER2 status of tumour 
tissue to determine molecular subtype is a routine aspect of breast 
cancer diagnosis in the UK. This provides an indication of the suitability 
of hormone treatments and Herceptin for each patient (Yeo et al., 2014). 
In addition to these well-established molecular practices, genomic ap-
proaches are also becoming implemented within routine NHS diagnostic 
processes. The hope attached to these techniques is that they will lead to 
a more precise understanding of cancer type, and better guide prognosis 
and treatment decision-making for individual patients. 
In 2013 a genomic technique, gene expression profiling, was 
approved for use within the UK NHS for a defined group of patients with 
early stage ER/PR+, HER2-and LN- breast cancer (National Institute for 
Health and Care Excellence, 2018). This cancer type is highly responsive 
to hormone treatment and associated with a good prognosis, with some 
patients avoiding adjuvant chemotherapy. The stratification of this 
group of patients into those who will and will not receive chemotherapy 
is emblematic of precision medicine. In the UK today this is aided by 
prognostic algorithms, which draw on information about the patient and 
their tumour markers to calculate an estimation of chemotherapy 
benefit. However, for a small proportion of these patients, a recom-
mendation for chemotherapy can remain elusive following use of these 
tools. It is at this point that gene expression profiling may be requested 
by NHS clinicians. 
The first gene expression profiling platform approved for NHS use in 
the UK was the US-developed Oncotype DX test. This test analyses 21 
genes in tumour tissue taken at surgery to develop prognostic informa-
tion (the likelihood of cancer recurrence), and based on this an estimate 
of chemotherapy benefit. Today this test has been adopted across the UK 
NHS to inform chemotherapy decision-making. The addition of gene 
expression profiling to existing practices of subtyping reflects the fact 
that clinically and within the laboratory, the number of procedures and 
tests undertaken on breast tumour samples is increasing. As a conse-
quence, diagnostic processes are becoming more divergent among in-
dividual patients (for example, some patients’ samples are amenable to 
further classificatory practices to determine treatment, while for some a 
treatment recommendation is clear from an earlier stage), and more 
protracted. An important question for sociologists is how these wider 
approaches to molecularization for driving more individualised and 
precise diagnoses impact patients’ experiences of cancer. 
Across medical sociology, a number of scholars have considered 
personal experiences of breast cancer diagnosis (e.g. Liamputtong and 
Suwankhong, 2015; Sulik, 2009), including of molecular diagnostics 
through the case of germline BRCA1/2 genetic testing (Hallowell et al., 
2004; Hesse-Biber, 2014). Using ethnographic methods, Day et al. 
(2017) explored patient and practitioner experiences of genomic tech-
niques to stratify treatment within NHS breast cancer care, concluding 
that in this setting these practices “promoted less rather than more in-
tegrated, personalised and seamless care” (p155). Though experiences of 
breast cancer diagnosis more broadly have often been the focus of social 
scientific enquiry, less in-depth attention has been given to the 
well-established processes of diagnostic classification used to identify 
breast cancer subtypes and guide treatment decision-making. Consid-
eration of routine diagnostic processes in cancer is important because 
these impact patient interpretations of their disease and treatment de-
cisions, but also because these processes have the potential to become 
reconfigured with the introduction of genomic techniques. 
In this article, we explore women’s accounts of being diagnosed with 
early stage ER/PR+, HER2-and LN- breast cancer, focusing on patients 
who have experienced Oncotype DX testing as part of this process. We 
discuss experiences of well-established clinical diagnostic pathways to 
identify their specific cancer type, then turn to accounts of the Oncotype 
DX test. Contributing to literature on the sociology of diagnosis, we 
introduce the concept of ‘diagnostic layering’ to make sense of how the 
multitude of diagnostic processes in oncology, which in the UK today 
routinely draw on molecular and genomic techniques, shape patients’ 
experiences of being diagnosed with breast cancer. First, we outline 
some of the sociological approaches to diagnosis that have informed our 
analysis. 
1.1. Diagnosis as a process and system of classification 
In recent years, the study of diagnosis has become firmly established 
as a ‘sociology’, with in-depth examination of the procedures and ex-
periences of diagnosis providing insight into the wider social and 
structural conditions within which it occurs (Jutel, 2015), but also 
showing how diagnosis acts upon social worlds (Pickersgill, 2014). So-
ciologists have demonstrated that diagnosis is a both a process shaping 
patient and professional experience, and also a system of classification 
working to organise disease and direct treatment (Jutel and Nettleton, 
2011). Two fundamental classification practices within medicine are the 
acts of ‘lumping’, whereby broad categories are created highlighting 
connections and similarities between conditions, and ‘splitting’, which 
emphasises specificity and difference (Zerubavel, 1996). Joyce and 
Jeske (2020) describe the fine-tuning of diagnostic categories through 
lumping and splitting as an iterative and ongoing process, requiring 
adjustment as new tests and treatments are developed and new knowl-
edge is produced. 
Once established, diagnoses can be acted upon through the estab-
lishment of a corresponding prognosis and treatment plan (Jutel, 2009). 
Diagnostic techniques thus have productive effects within the clinic, 
with powerful consequences for patients, clinicians and the wider 
organisation of healthcare practice. However, social scientists have 
shown that the messiness of disease means medical classifications are 
uncertain and always ‘configurationally complex’ (Bowker and Star, 
1999: 172) as they attempt to bind the “biological, the technological, the 
social, the political and the lived” (Jutel, 2009: 294) through assem-
blages of a range of human and non-human actors (see Gardner et al., 
2011; Locock et al., 2016). 
By tracing diagnosis in practice, existing work has shown that 
diagnostic categories and procedures can be experienced by patients in 
varying ways; for example as disembodying in the case of medical 
technologies (Daly, 1989), but also as empowering, by providing reas-
surance (Blaxter, 2009) or opportunities to work strategically with 
diagnostic categories (Joyce and Jeske, 2020). Sociologists have shown 
that the road to diagnosis is rarely straightforward for individuals and 
those treating them, often experienced as negotiated (Madden and Sim, 
2006), and generative of uncertainty (Timmermans et al., 2017; Swal-
low, 2020). This has been discussed even in relation to conditions with 
well-established and apparently stable classificatory procedures. For 
example, Purkis and Van Mossel (2008) show that in the face of a 
multitude of technologies and tests, patients navigating the Canadian 
breast cancer system experienced diagnosis as “neither clear or complete 
but always in motion, frequently being revised” (p143). The authors 
found that diagnosis and treatment plans were continuously negotiated, 
and therefore conceptualise cancer as a contested illness. This charac-
terisation likens cancer to medically unexplained conditions, which can 
situate patients in a ‘diagnostic limbo’ (Nettleton, 2006) and leave them 
unable to access treatment - demonstrating the close relationship be-
tween these clinical activities (Dumit, 2006). 
Genomic techniques have further reconfigured the relationship be-
tween diagnosis and treatment, and the wider healthcare systems within 
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which these practices take place (e.g. Bourret et al., 2011; Timmermans 
et al., 2017). Troubling the sociological delineation of diagnosis as a 
distinct process, Bourret et al. (2011) have shown how novel molecular 
techniques can conflate diagnostic, prognostic and therapeutic work. 
Diagnosis and treatment become intimately connected within molecular 
approaches, as therapeutic decision-making becomes directly related to 
knowledge of cancer pathogenesis and progression (Keating and Cam-
brosio, 2013). 
Despite anticipations for genomic techniques to remedy diagnostic 
uncertainties, particularly in rare genetic diseases where patients 
seeking a diagnosis often hope these “advanced” tools “may bring their 
search to an end” (Timmermans et al., 2017: 442), their mobilisation 
does not always provide a resolution. These techniques can produce 
uncertain results and interpretive dilemmas for clinical teams (Skinner 
et al., 2016). This has also been discussed in relation to efforts to 
mainstream genomic technologies into routine care. Here the fallibilities 
of novel techniques, and a lack of capacity to interpret complex genomic 
information, can demand careful work from healthcare practitioners to 
manage patients’ expectations for treatment (Kerr et al., 2019). 
In this article, we draw on qualitative interview and observational 
data to explore these issues in the context of routine cancer care in a UK 
setting. We contribute to existing literature by considering the molec-
ularization of breast cancer diagnosis, with specific reference to the 
identification of cancer markers and gene expression profiling (Oncotype 
DX). Drawing on personal accounts we introduce the concept of ‘diag-
nostic layering’ as a heuristic device to make sense of how these pro-
cesses of classifying breast cancer shape patient experience. Due to the 
numerous laboratory analyses now conducted on breast tumour tissue, 
patients receive information about their cancer in ‘layers’, as separate 
rounds of clinical information are relayed to them by their clinician. This 
can be over a period of many weeks. These layers aim towards a more 
refined diagnosis, as they work to ‘lump’ the suspected tumour as a 
cancer, and then ‘split’ the cancer into a distinct subtype and subse-
quently direct treatment. The concept of layering thus entails both of 
these activities, but additionally captures the temporality of these pro-
cesses, which occur across various time points and may require repeti-
tion. As several layers of diagnostic information from diverse sources are 
collated to subtype breast cancer today, including histopathological, 
molecular and genomic analyses, we contend that diagnosis is tempo-
rally extended, as well rendered partial (incomplete) and subject to 
change (mutable). This can impact patients’ expectations for diagnostic 
pathways and care. Despite anticipations for genomic testing to finalise 
the diagnostic process, patient accounts reveal a more complex picture. 
We show that the incorporation of these test results into treatment 
decision-making is not straightforward, but informed by diagnostic in-
formation derived from established tools, and powerful cultural imagi-
naries of cancer and chemotherapy. 
2. Methods 
The data on which this article is based is drawn from a large multi- 
sited research project considering how genomic techniques in cancer 
are impacting patient and practitioner experiences of cancer care. As 
part of this project a range of health professionals were interviewed, 
with some emphasising the importance of attending not only to novel 
genomic techniques, but those already established in routine care such 
as gene expression profiling. As such, following NHS ethical approval 
(REC reference 16/YH/0229) and with the help of key oncologists and 
research nurses, we recruited and interviewed 18 patients who had 
received Oncotype DX testing as part of their cancer care at NHS sites 
within England and Scotland. We also conducted four observations of 
consultations where patients (all with an accompanying family member) 
discussed treatment decisions in light of Oncotype DX results. Interviews 
with oncologists who had used the technique with their patients were 
also conducted, as well as observation of online discussions of Oncotype 
DX testing, with these findings presented elsewhere (Kerr et al., 2021; 
Ross et al., 2019). 
Interviews with patients took place between June 2017–August 
2019. Interviews were semi-structured and began by seeking a narrative 
account of the interviewee’s symptoms, suspicions and their path to 
diagnosis. Interviews also covered engagements with gene expression 
profiling specifically, including how the technique was explained by 
their clinician, any independent research they had undertaken about the 
technique, how they made sense of their Oncotype DX result, subsequent 
treatment decision-making and ongoing legacies of the result. In-
terviews lasted between 45 min to up to 2 h, were audio-recorded and 
transcribed verbatim. The four observations of consultations took place 
in June and July 2017. These involved a researcher being present at 
consultations where treatment decisions were discussed and formalised 
by patients following their Oncotype DX result. These lasted up to 1 h. 
Fieldnotes were taken by hand, before being typed and shared with the 
research team. 
Analysis drew on techniques of constant comparison (cf. Charmaz, 
2006) and thematic analysis. Transcripts and fieldnotes were shared 
between team members, and read and compared in an iterative process 
moving back and forth between individual transcripts and the complete 
set of interviews and observations. Similarities and differences were 
noted within and between transcripts and fieldnotes, with reference to 
data from the wider project and sociological literature on diagnosis and 
cancer. Key themes were developed as a result of this process. These 
included ‘treatment decision-making’ ‘quantification of risk’, ‘embodi-
ment’, and ‘clinical judgement’. The theme of ‘layering’ began as an in 
vivo code that succinctly described participants’ experiences of gradu-
ally gaining various levels of information about their cancer over time. 
After going back to the data with this theme in mind, we developed the 
concept of ‘diagnostic layering’ to convey the ways in which, from a 
patient perspective, molecular and genomic information shape experi-
ences of contemporary breast cancer diagnosis. We also attended to how 
processes of diagnostic classification were further shaped for these 
participants in light of gene expression profiling; in ways that could both 
end but also extend the diagnostic process. 
In what follows, we present women’s accounts of ‘diagnostic layer-
ing’, and discuss the implications of this for chemotherapy decision- 
making and wider experiences of cancer. In the first section we attend 
to how participants discussed well-established routine diagnostic pro-
cedures for breast cancer. We share experiences of several of the ‘diag-
nostic layers’ articulated by patients. These included provisional 
diagnoses of cancer at the breast clinic, the molecular classification of 
cancer following pathology results (including informal characterisations 
of their cancer type by clinicians), and for some the re-casting of their 
cancers after further pathology. In the second section we attend spe-
cifically to personal accounts of Oncotype DX testing. We show how this 
aspect of diagnosis became intimately connected to treatment, and 
related to this, how some women described this as a ‘final’ layer of 
diagnostic information. However, for others this information could 
introduce further uncertainties and extend diagnostic processes. We end 
by considering the implications of genomic techniques for patients’ 
experiences of cancer diagnosis. 
3. Diagnostic layering in early stage breast cancer 
Many participants’ experiences of diagnosis began with an embodied 
awareness of a lump in their breast, but for a minority this followed a 
recall after routine screening. At the time of our interviews patients had 
all been treated surgically, and had commenced or were due to embark 
on chemotherapy and/or radiotherapy following the results of gene 
expression profiling. 
For most interviewees, the initial labelling of suspicions about a 
lump or a blur on a mammogram as cancer took place in the breast 
clinic. The clinic, described by Dette as a “one-stop shop”, provided 
women with a mammogram, ultrasound and, if necessary, a biopsy on 
the same day. Valerie described her experience at the clinic as like a 
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“conveyer belt”. The very experience of being in the clinic could serve as 
a form of diagnosis in itself. Several participants described a number of 
‘cues and clues’ that led them to anticipate a diagnosis of cancer before 
being formally told (cf. Locock et al., 2016). These included being 
re-approached by the nurse for a second mammogram (Valerie), but also 
observing the waiting room and noticing other attendees leave after 
each tier of investigations, whilst they and a dwindling group of women 
remained (Dette, Eve). 
At the end of their visit, which for some lasted the entire day, a 
discussion with the oncologist at the breast clinic could represent a first 
layer of diagnosis for participants. Shortly after their final biopsy, a 
verbal indication of cancer could be communicated to women. For some 
this was unequivocal, coming as a shock for Bethany who exclaimed 
“how can she say that when they’ve not got the biopsy result?“. For 
others this was implied. Linda was told “don’t be surprised” if the pa-
thology report indicated cancer. All were told that more information 
would be available following the biopsy results, which could take up to 
two weeks. 
3.1. Classifying a ‘good’ cancer 
Biopsy results provided a further strata of information to participants 
about their cancer; and in some cases it was not until this point that 
cancer was confirmed. The pathology report both confirmed a diagnosis 
of breast cancer (a ‘lumping’ of the tissue’s characteristics as 
‘cancerous’), but also provided information about the tumour’s receptor 
status e.g. ER+, HER2- (the ‘splitting’ of their cancer into a particular 
subtype). In describing their diagnosis during interviews, almost all 
disclosed the receptor status outlined in this first pathology report, and 
some the size and grade of their tumour, appreciating that this infor-
mation was specific to their cancer. The heterogeneity of breast cancer 
was therefore recognised by participants, gleaned not only from their 
pathology results but also from discussions with clinicians. In two con-
sultations, we observed the oncologist explain to the patient that “breast 
cancer is a very big family of cancer” (Observation2 July 2017) and 
“breast cancer is not one cancer” (Observation1 July 2017). 
Commonly encountered within interviews were reports of clinicians 
describing their subtype of the disease as a ‘good’ cancer. This was 
inferred through explanations of their cancer as “early stages” (Elisa), 
“treatable” (Lois) and “low risk” (Lillian), or in some cases women’s 
cancers were explicitly described as ‘good’. Eve had attended the breast 
clinic and was informed that something “sinister” had been found on her 
ultrasound, leading to several biopsies later that day. During the dis-
cussion with the oncologist she was advised of possible scenarios and 
treatments, but unlike other participants had not been told to expect a 
diagnosis of cancer. Her next appointment was with a different clinician 
two weeks later. She recounted: 
So when I went in and he said, erm, ‘oh well, it’s all good news’. So of 
course, I was like, ‘oh yes!‘, do you know what I mean?’ And he 
must’ve saw my face, and he’s like, ‘whoa, whoa, what have you 
been told?’ Right, and I was like, ‘well, basically, in no uncertain 
terms, I had cancer, but it, the word wasn’t used’ … And he went, ‘oh 
yes, you’ve got cancer’, he said, ‘but it’s a good cancer’. 
This way of communicating her first formal diagnosis discursively 
configures Eve’s cancer subtype in a positive way, and as distinct from 
the widely accepted understanding of cancer more generally as ‘bad 
news’. A configuration of these women’s cancers as good was also 
achieved beyond linguistic performance. As discussed by Kazimierczak 
and Skea (2015), this was embedded within a range of socio-material 
practices and relations (see also Gardner et al., 2011; Locock et al., 
2016). For participants in this research, these arrangements comprised 
their molecular markers which were discussed favourably by clinicians, 
and as we observed in one consultation, sometimes illustrated visually 
with pen and paper (Observation2 July 2017). This added to a sense of 
successful treatment prospects and positive outlook: 
When they gave me the results of the oestrogen, the ER-positive, they 
said that was good because the tamoxifen would be very effective 
and so the consultant was “that’s really good.” Julie 
This layer of information largely configured our participants’ cancers 
in ways that inspired relief and optimism. Significantly these positive 
interpretations of their cancer-type impacted upon anticipated treat-
ment pathways, which were again largely discussed optimistically in the 
first instance, and without mention of chemotherapy. Dette was told in a 
“matter-of-fact” way that “it’s very small, it’s very early, you’ll find out 
about radiotherapy but you have to have surgery first.” Similarly Elisa 
was told “yeah you have got [cancer] but early stages. So we’ll just give 
you surgery then radium”. 
Others, however, were given a more tentative outlook, being told 
that treatment depended upon further factors that would only be 
resolved following surgery. Valerie was told about her molecular 
markers in a positive way, but that though appearing favourable there 
was uncertainty regarding lymph node involvement: 
So I was HER2 negative so that helped. Erm, and then obviously 
whether it was in the lymph nodes or not. From the ultrasound they, 
they thought it wasn’t, but they weren’t gonna confirm that until 
results from the surgery. 
Though tentative for several participants, such initial depictions of 
their cancer as ‘good’, and for some, easily treated, are significant. These 
impressions paved the way for the shifts in anticipated treatment 
pathways that were to come, as additional layers of diagnostic infor-
mation emerged; each achieved through fresh configurations of socio- 
material practices. 
3.2. The provisionality of breast cancer diagnosis: reconfigurations of 
cancer and treatment 
As outlined above, initial biopsies taken at the breast clinic gave a 
degree of diagnostic information about our participants’ cancers, and in 
some cases, indication for treatment. However, further pathology ex-
amination following surgery meant that for some, their ‘good’ diagnosis 
and related anticipations for treatment could be reconfigured. 
As in Valerie’s extract above, surgery was presented to participants 
as the point at which uncertainties about treatment could be resolved. 
However in practice, surgery could result in initial understandings of the 
tumour being rendered obsolete, and in some cases the designation of 
their results as a ‘grey area’. This could require further intervention to 
generate an additional layer of diagnostic information. Some of these 
uncertainties, notably to do with the cancer’s size, could be clinically 
acted upon. For six of those we interviewed, following breast conserving 
surgery to remove the cancerous tissue (a lumpectomy) it was discov-
ered that the operation had not removed an adequate margin of cancer- 
free tissue around the tumour. These six women therefore underwent 
one or more re-excisions to remove all of the cancerous tissue, and re- 
establish the size of the tumour. 
Other aspects of the cancer were also altered following diagnostic 
information from surgery, with ‘good’ cancers rendered potentially 
‘bad’ cancers. In most instances this was due to confirmation of, or in 
three cases a shift in, the cancer’s grade (rate of growth). This was the 
case for Lois: 
I got the results from the surgeon and that was when he said “oh, 
your lymph nodes were clear and all the cancer’s been removed” so 
that was a great boost, so that was super. But the cancer had moved 
from a grade 2 to a grade 3 category so it was worse than first 
expected. 
The transformation of their cancer to a higher grade provoked a shift 
in language from clinicians. Women reported their doctors now using 
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terms including “aggressive” (Bethany, Dette, Elisa), “high grade” (Zoe), 
and “fast growing” (Valerie, Eve). In some instances surgery uncovered 
what was described as a “slight” or “tiniest” spread to lymph nodes, 
which was the case for Lillian, Jane, Julie and Alice. In situations such as 
these, where new or altered information about the tumour was intro-
duced, anticipated treatment pathways were (again) rendered uncer-
tain, and chemotherapy could be raised as a possibility where it had not 
existed before. Due to previous layers of information pointing to a ‘good’ 
cancer, Elisa, Dette and Lois had not anticipated being offered chemo-
therapy, with Chrissy also unsure as to why the treatment had suddenly 
been introduced when “the cancer had all gone from surgery”. Linda had 
not considered chemotherapy because of heart condition, which had 
compelled her clinicians to “try and avoid that”. The introduction of 
chemotherapy came as a “blow” for these women. The instability of 
diagnosis as related to treatment could work both ways, however, as two 
participants (Susan and Julie) had expected chemotherapy, which was 
then called into question following surgery. 
As well as the initial incompleteness of diagnostic information 
described in the extracts above, which participants (and their clinicians) 
gained gradually in layers, interviewees therefore also pointed to the 
mutability of diagnosis, particularly following surgical intervention. 
Subsequent layers of information could both add to and refine existing 
understandings of the tumour and cancer type, but in some cases called 
previous layers into question. Paradoxically, though diagnosis is 
generally engaged upon with a view to fixing a disease classification, 
and discern treatment along with “a sense of where the road ahead may 
lead” (Jutel, 2009: 288), for these women the diagnostic process could 
be experienced as partial and subject to revision, as progressive layers of 
information invalidated previous knowledge of the tumour, shifted 
anticipated care pathways, and for some introduced the possibility of a 
feared treatment. Dette described her experiences of receiving diag-
nostic information progressively over time as “unsettling”: 
When you do ask questions they do say “we can’t actually really tell 
you until we’ve done this” you know, until they’ve done the biopsy. 
And then when they’ve got the biopsy they say “oh, actually, we’re 
going to do a better test when they actually take the lump out” … I’ve 
been told a lot “we don’t have a crystal ball”. 
Jane experienced diagnosis as a series of “stages”, with waiting for 
results the most difficult aspect. Hazel explained that thanks to advice 
from a friend who’d also been treated for breast cancer, she had been 
prepared for “false horizons” and as such did not take anything in her 
planned treatment regime for granted. She described being “always 
open to whatever happens next, without, without holding on too much 
to what the, the considered next stage ought to be”. Bethany described 
her experience of receiving contradictory layers of information about 
her cancer, and the implications of this for treatment, as a “roll-
ercoaster”. However, she also sympathised with this approach: 
Being told that because of the Herceptin [HER2] result I didn’t need 
chemotherapy, you know, I felt very positive and I told all my family. 
Which is why then a few days later, or whenever, I’m told “it’s grade 
three and you probably will”, em, I had to then tell my family that … 
But I feel that’s just the way it has to be because that’s just part of the 
process really. You know, so it’s about, sort of maybe eliminating, 
you know, what it is not, and working out what it is really. And the 
clinicians have to do that and it takes a wee while. 
Bethany’s account shows that though it may be subsequently revised, 
each layer of information had palpable consequences for patients. 
The extracts from both Hazel and Bethany point to the significance of 
diagnostic information not as an end in itself, but with regards what this 
meant for treatment. This was a key issue for many of those we inter-
viewed, who discussed diagnostic details as ‘good’ or ‘bad’ with refer-
ence to their implications for chemotherapy. However, for the women in 
our research, the assessment of diagnostic information through 
established tools was insufficient to determine a recommended treat-
ment regime, and further layers of clinical information about the cancer 
were required. In this type of early stage breast cancer, prognosis now 
came into play. For those we interviewed, prognostic information was 
derived from an algorithm freely available to clinicians and the public, 
NHS Predict. The women interviewed here were unique, however, in that 
this layer of information proved inconclusive. For those in our research, 
estimations of chemotherapy benefit placed women in an ‘intermediate’ 
range, characterised by many of our participants as a ‘grey area’. A 
further round of information was sought by their clinicians to refine 
these estimations, accessed in the form of a genomic technique; Onco-
type DX. Below, we explore how the introduction of Oncotype DX added 
another ‘layer’ to patients’ experiences of diagnosis, in ways that could 
both finalise, but also extend, the diagnostic process. 
4. Gene expression profiling 
In the context of already protracted experiences of diagnosis, clinical 
uncertainty around treatment was difficult for participants to come to 
terms with. Patients had been given a diagnosis of a “scary” disease 
(Eve) “that kills” (Susan), and which inspired painful recollections of the 
deaths of friends or family members. Though contemporary medicine 
has relieved some of the historic devastation caused by the disease and 
radical treatments (Löwy, 2009), cancer remains culturally feared, in 
part due to its uncertainties and unpredictability. As described by Jain 
(2013), the catalogue of explanations, treatments and statistics faced by 
patients render the disease virtually impossible to navigate. In the face 
of cancer, interviewees discussed wanting to do all they could to treat 
and prevent its return, including undergoing chemotherapy. As Eve 
expressed “I want every treatment I can get, do you know what I mean, 
to stop it coming back.” However, alongside fears of cancer and its re-
turn, many of those we interviewed were equally anxious at the prospect 
of the treatment, which they associated with hair loss, compromised 
immunity and long-term side effects (see Bell, 2009). This again 
included Eve, who described memories of her mother being “ravaged” 
by chemotherapy. 
It is within this context that where a clinician had so far guided them 
with regards treatment decisions, providing some solace in the face of 
these oncological uncertainties, unknowns suddenly became openly 
acknowledged. Further, the responsibility for addressing these could be 
passed to patients: in the absence of a recommendation from the prog-
nostic algorithm, many interviewees had been asked to choose whether 
or not to proceed to chemotherapy. Lois described this as her oncologist 
“laying the decision at your door”, and along with others, experienced 
this as emotionally fraught. One patient observed in Observation2 July 
2017 said that this placed her “between a rock and a hard place”, an 
idiom also used by Alice who elaborated further: “I didn’t want to take a 
risk of not having chemo if I needed it. But I didn’t want to have, take the 
risk of taking chemo if I didn’t need it.” Below, we demonstrate how the 
layer of information provided by gene expression profiling could both 
attend to the emotional difficulties of this situation by solidifying a 
diagnosis and enabling a treatment decision, but also prolong the 
diagnostic process further by introducing additional contradictions and 
complexities. 
4.1. A ‘final layer’ of diagnosis? 
Oncotype DX was represented by clinicians, and understood by pa-
tients, as having the potential to resolve clinical uncertainties sur-
rounding treatment. In one consultation we observed the following 
exchange: 
Because the patient is ‘so young’ [early 40s] the consultant predicted 
a good prognosis. She added that without the Oncotype test result [i. 
e. with just the NHS Predict result], it might have appeared that the 
patient doesn’t need chemo but with this result it shows the benefit 
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… The consultant said NHS Predict gives you ‘a rough average’ but 
because breast cancer is a big group of diseases, this is ‘where 
Oncotype comes in’. Observation1 July 2017 
Here, gene expression profiling is described as providing a more 
specific estimation of chemotherapy benefit, contrasting with the ‘rough 
average’ generated by NHS Predict. The notion that gene expression 
profiling provided a level of refinement not available from other tools 
was echoed by interviewees. Both Julie and Bethany described the test 
as providing “more specific” information about their cancer. Bethany, 
who described Oncotype DX as a “state of the art” test, and “most 
advanced that’s available” explained this in more detail: 
As far as I was concerned, this test, as it had been described to me, 
meant that this was very particular to me, in a way. You know, this 
was a sort of DNA profile of my tumour and, to some extent, milder 
extent, of me and therefore if that test said I needed [chemotherapy] 
then I would definitely have done it. 
Due to the fact that the test generated a recommendation based on 
analysis of her own tumour tissue, Alice discussed the test as providing 
“scientific fact”, which she contrasted with the “expertise” of her clini-
cian. Julie noted that the result “will make me feel I’m not making a 
hunch decision, I’m making a decision based on actual science”. The fact 
that the test was “personalised”, gave Hazel “confidence” in the subse-
quent recommendation to forgo chemotherapy. This was echoed by 
Bethany who, again demonstrating an appreciation of the diversity of 
breast cancer, explained “it does make me feel more confident that this is 
about me and em, that attention is being paid to me and the sort of 
tumour I have”. 
Due to its ability to provide a “personalised” recommendation, these 
interviewees portrayed Oncotype DX as providing a layer of information 
to inform their treatment decision which surpassed others. Though 
previous diagnostic techniques had of course also been personalised, 
involving molecular analysis and pathological examination of their 
tumour tissue, treatment recommendations had been more heavily 
developed from clinical judgement, assisted by tools such as the NHS 
Predict algorithm. Whilst such algorithms and Oncotype DX perform the 
same task – estimate recurrence risk to develop a chemotherapy 
recommendation – the fact that Oncotype DX’s treatment recommen-
dation was directly developed from their “DNA profile”, and thus 
“personalised”, marked the tool as distinct for some participants, and as 
inspiring a particular confidence. 
For these interviewees, the test result was represented as integral to 
their decision about chemotherapy. Those with a ‘low risk’ score 
described their result as allowing them to more confidently say no to 
chemotherapy: 
So by getting the test … then that gave us the second opinion really to 
say that no, I didn’t need the chemo. Lois 
So I had the test done, so I had the scientific back-up, almost, to say, 
yeah, you really won’t benefit [from chemotherapy]. Alice 
Similarly, those with a high risk score, despite some being disap-
pointed that chemotherapy had been recommended as a treatment op-
tion, also welcomed their Oncotype DX results. Felicity represented the 
test as leaving her with no choice but to proceed with the treatment: 
I had, well, a score of twenty-seven, which was a no, no-brainer, 
really. That’s, that’s you at a high risk so … So in that way that 
was reassuring. [Laughs]. Do you know, in an awful way. In an awful 
way. It was like well, I was glad that it was such a definitive result. 
Here, Felicity describes the ‘layer’ of diagnostic information pro-
vided by Oncotype DX as “definitive”, contrasting with previous clinical 
assessments of her tumour. Felicity had faced particular uncertainties 
around adjuvant chemotherapy having received hormone treatment 
prior to surgery, and had found chemotherapy decision-making 
“impossible”. She welcomed the Oncotype DX result, which squarely 
placed her at high risk, providing a clear recommendation for chemo-
therapy. For these participants, the fact that the test result directed 
treatment decision-making in this way distinguished it from previous 
layers. As well as being “definitive” in the sense of not able to be tech-
nically surpassed by other techniques (“state of the art”), the perceived 
finality of the Oncotype DX result can also be linked to the fact that it 
directly recommended a treatment. Due to their fears surrounding 
recurrence, but also of chemotherapy, the discernment of the ‘right’ 
treatment was an important outcome of the diagnostic process for in-
terviewees. For the participants above, by successfully resolving un-
certainties around treatment, no further ‘layers’ of diagnostic 
information were needed. Bethany, who earlier likened breast cancer 
diagnosis to a ‘process of elimination’, described the test as a ‘final 
diagnosis’: 
It just really meant that it was a very individualised, you know, that it 
was another layer, a bit like peeling an onion until you get to the final 
bit, you know, the final sort of diagnosis really. 
Here Bethany points to an alternative conceptualisation of diagnostic 
layering, where various components of information are gradually un-
covered until the most refined is provided by Oncotype DX. Importantly, 
Bethany discussed this information as a ‘final’ layer because, due to the 
fact it was “individualised”, she could now make a decision about 
chemotherapy. Complementing Dette’s earlier description of the diag-
nostic process thus far, Julie similarly proclaimed that the test acted as 
“a bit of a crystal ball, you know, and g[a]ve me something to actually 
make a decision on”. 
In the context of uncertainty surrounding a feared treatment, 
Oncotype DX was therefore welcomed by many participants interviewed 
for this research. The test was seen to solidify diagnoses which had 
previously been experienced as fluid and changeable. It ‘finalised’ 
diagnosis in two ways; through its provision of ‘state of the art’ and 
personalised diagnostic information, which could not technically be 
surpassed, but also by clearly directing treatment, ending uncertainties 
surrounding this important aspect of their cancer care. Nevertheless, 
receiving the Oncotype DX score did not straightforwardly finalise the 
diagnostic process for every patient. As we now discuss, the introduction 
of the technique also had the potential to further unsettle paths to 
treatment, particularly in terms of its blurring of diagnosis and 
prognosis. 
4.2. Meanings of gene expression profiling and the persistence of 
provisionality 
As discussed in the first part of our findings, diagnostic information 
derived from established tools had the potential to reconfigure initially 
‘good’ cancers as potentially ‘bad’ cancers. This rendered initial di-
agnoses as incomplete and mutable, with associated treatment plans 
experienced as a series of ‘false horizons’ (Hazel). Novel genomic 
techniques such as Oncotype DX are presented as bringing finality, with 
clinicians often presenting such techniques as “the most comprehensive 
test” (Timmermans et al., 2017: 442). However, genomic information 
can sometimes introduce unexpected or contradictory results, as we 
heard during our interviews, causing confusion for patients and further 
disrupting diagnostic journeys. 
In some cases, our interviewees’ Oncotype DX results conflicted with 
previous layers of diagnostic information. Where these contradictions 
arose, unlike in the extracts above the genomic result was not always 
taken at face value, but required further interpretation. During the 
earlier stages of diagnosis, Lillian had been told “on two or three occa-
sions” that hers was a “low risk cancer”. However, Oncotype DX indi-
cated that chemotherapy would be recommended for her. Having 
learned her result she decided that chemotherapy was “inevitable”, and 
welcomed the presentation of statistics and percentages alongside her 
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score to help her make her decision. However, she also felt confused 
about her result, a feeling which lingered beyond her consultation: 
It’s only when I got home and I looked at my notes, I almost couldn’t 
marry the two things together. Him saying it’s low risk but then me 
being a 29 on the Oncotype. 
This was also the case for Dette, for whom the possibility of 
chemotherapy first arose following surgery. Despite being consistently 
advised that her cancer was “small” and “early”, her Oncotype DX score 
placed her in the ‘high risk’ category. She discussed her confusion about 
this with her oncologist: 
‘You don’t have to be terrified’ [the oncologist] said, ‘you, your 
prognosis is incredibly good.’ And this is what’s difficult to under-
stand, is why give me chemotherapy? And she said ‘it’s just because 
we don’t want you to get it again.’ 
In these women’s reflections, their cancer had been positioned as 
‘good’ based on previous layers of information, but rendered a ‘high risk’ 
cancer by the Oncotype DX test. This apparent contradiction is mitigated 
by the oncologist above through her distinction between Dette’s cancer 
in the present (which had been successfully excised), and a possible 
cancer recurrence in the future. This demonstrates that the ambiguity of 
Oncotype DX as a prognostic or diagnostic tool, as well as having im-
plications for practitioners (Bourret et al., 2011), can impact patients. 
All of those we interviewed emphasised the value of Oncotype DX as 
related to its implications for chemotherapy decision-making, an exer-
cise most often associated with diagnosis and generally situated in the 
present. This is inscribed within the very name of the test itself, through 
use of the abbreviation DX. However, gene expression profiling differed 
from earlier assessments of their cancer, by drawing on predictive in-
formation. Where this information did not correspond, it unsettled pa-
tients such as Dette and Lillian. The significance of this for sociological 
studies of genomic technologies is that though often presented as a most 
“advanced” and “comprehensive” technique (Timmermans et al., 2017: 
442), in these examples genomic testing did not render previous layers 
of diagnostic information obsolete. Despite a clear indication for treat-
ment, Dette sought further discussion of her Oncotype DX score in light 
of previous results. These became enmeshed in her interpretation of the 
score and its implications for treatment, with their significance not 
diminished by this novel technique. 
This was also the case for Wendy and Zoe. They both consulted with 
their oncologist to further interpret the meaning of Oncotype DX for 
treatment, despite both attaining a clearly low score. Following pa-
thology results after a second surgery, Zoe had interpreted that her 
cancer was ‘high risk’ due to it being a high grade. She raised this with 
her oncologist: 
I was a bit worried with a high grade on its own, it would be an 
indication for, for chemo, and, um. So I didn’t, I didn’t want to 
appear that I wanted chemo but I just wanted to make sure that not 
having it is the right thing to do. And, um, so she said, ‘no, no, no, at 
score 7 we would definitely not offer you chemo’. 
Zoe’s involvement of the oncologist in translating the Oncotype DX 
result into a treatment decision, despite a clearly ‘low risk’ result, was 
shaped by a persistent unease about declining chemotherapy, in the 
context of a previous layer of diagnostic information which had labelled 
her cancer as ‘high grade’. She found it difficult to unequivocally accept 
the invalidation of this earlier information by the test, being unsure as to 
whether forgoing chemotherapy was “the right thing to do”. Zoe implies 
a felt imperative to embark upon chemotherapy to successfully treat 
cancer, despite her wish to avoid the treatment. This was also alluded to 
by Dette who discussed the sociocultural entwinement of cancer and 
chemotherapy: “you’ve got cancer, it’s like “oh my God!” And every-
body knows that chemotherapy gets rid of it”. This felt imperative was 
also invoked by a clinician in an appointment we observed, where an 
‘intermediate’ Oncotype DX result was discussed with a patient. 
[The consultant] reiterated that it’s difficult for him to advise [on 
chemotherapy] one way or another. But he added ‘what if’ seems to 
be a ‘powerful driver’, i.e. ‘doing everything I can’ mentally. The 
patient said ‘it’s no-brainer for me then’. Observation2 June 2017 
In these examples, where the result disrupted prior configurations of 
their cancer, the information provided by Oncotype DX is presented a not 
quite representing a ‘final’ layer of diagnosis, but as requiring further 
interpretation. Dette, Zoe and Wendy therefore sought further discus-
sion with their clinicians about the meaning of their Oncotype DX result, 
despite it providing a clear indication for treatment. As we have shown, 
their reasons were twofold. First, the result had contradicted previous 
layers of diagnostic information about their cancer. This demonstrates 
that all diagnostic layers in their totality remained important to par-
ticipants, and were not simply surpassed by the information derived 
from genomic testing. Secondly, persistent fears about cancer and its 
possible recurrence meant that even in the context of a ‘low risk’ result, 
some reported anxieties about foregoing chemotherapy, despite this 
clear recommendation from an “advanced” test. Though previously 
unattainable, following Oncotype DX testing Dette, Zoe and Wendy were 
now given an explicit treatment recommendation by their clinician. For 
the patient in Observation2 June 2017, this remained elusive following 
an intermediate result, though a recommendation to proceed to 
chemotherapy was subtly implied by her oncologist. Importantly, this 
was not solely formulated based on his assessment of layers of diagnostic 
information, but also by drawing on the powerful discourse of ‘doing all 
one can’ to fight cancer. 
In these sections, we have observed some clinicians and participants 
discussing Oncotype DX results as remedying the partial and mutable 
experiences of diagnosis hitherto described by interviewees. However, 
not all interviewees represented the test in this way. For some, despite 
patient and clinician anticipations for genomic testing to bring finality to 
diagnostic journeys, the result was not depicted as definitive. Impor-
tantly, our analysis has shown that despite its imagined finality and 
superiority to other techniques, decision-making following Oncotype DX 
testing did not always incorporate the result unquestioningly. Instead, 
engagement with the result was complex and cautious, shaped by con-
figurations of the tumour developed through previous diagnostic layers, 
as well as persistent fears of cancer and its possible recurrence. 
5. Discussion 
Breast cancer is now widely viewed as a heterogeneous disease 
within clinical settings. We have outlined, from a patient perspective, 
the routine processes through which breast cancer comes to be split into 
distinct subtypes. Within the UK NHS, the subtyping of breast cancer has 
given rise to different therapeutic regimens for individual patients, with 
these intersected by varying patterns of surgical management according 
to the cancer’s size and spread. Breast cancer subtyping has become 
more refined, with an aim to ‘split’ diagnostic classifications falling 
under the ‘lumped’ category of breast cancer. The process of splitting a 
diagnosis of breast cancer entails several techniques, some well- 
established and others introduced only within the last decade. These 
developments have had consequences for patients as their tumour tissue 
becomes subjected to an increased number of diagnostic procedures, and 
as diagnostic information is delivered to them at several time-points. We 
have introduced the concept of ‘diagnostic layering’ to convey this 
contemporary experience of diagnosis as articulated by patients. 
As a concept, layering captures both the incompleteness of diagnosis, 
experienced as partial and unable to be confirmed until further layers of 
diagnostic information are attained, and also the mutability of diag-
nosis, which could become subject to change as new layers of diagnostic 
information are introduced. Shifts in understandings of their cancer 
could be challenging for those participants whose subtype had initially 
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been portrayed as unequivocally ‘good’, as this became invalidated by, 
for example, a designation of a higher grade. Despite patient hopes for it 
to resolve these uncertainties, the results of Oncotype DX testing could 
further unsettle previous diagnoses, shifting patients’ expected out-
comes and treatment pathways. For our participants, routine diagnosis 
thus entailed contradictions, and periods of navigating a ‘diagnostic 
limbo’ (Nettleton, 2006), likening experiences of early breast cancer to 
those of contested illnesses (Purkiss and Van Mosell, 2008). Interviewees 
gave descriptions of managing these uncertainties emotionally by 
anticipating ‘false horizons’, ‘preparing for the worst’, and taking their 
cancer care ‘one step at a time’. 
For our participants, the partial and protracted nature of diagnosis 
could be especially difficult to manage due to its direct implications for 
treatment; most notably adjuvant chemotherapy. Previous studies have 
shown how the ‘tangled web’ of 21st century oncology can blur prog-
nosis, diagnosis and treatment from the perspective of practitioners, 
with implications for professional jurisdictions (Bourret et al., 2011; 
Keating and Cambrosio, 2013). We have shown the implications of 
reconfigurations of these practices for patients, as they attempt to make 
sense of their cancer (risk) when assessed by a range of diverse and 
sometimes inconsistent clinical tools, deployed at various time-points. 
As a relatively recent addition to routine diagnostic processes in the 
UK, Oncotype DX testing is often touted as bringing certainty and closure 
to diagnosis in early breast cancer, particularly as it relates to treatment. 
Indeed, some participants’ experiences did accord with this narrative. 
Some described the technique as ‘finalising’ diagnosis, in part because it 
was viewed as ‘state of the art’ and ‘personalised’ when compared with 
previous diagnostic tools they’d encountered. This inspired confidence 
in its recommendation. Its finality was also related to the fact that in the 
face of an agonising decision, its result could provide a clear recom-
mendation for treatment. In these cases Oncotype DX testing might be 
understood in similar ways to the numerical biomarker tests described 
by Bell (2013), whereby in the context of “cancer’s semiotic ‘din’“, 
numerical results can provide a “reassuringly concrete buoy for patients 
to cling to” (p 134–5). 
However, gene expression profiling also had the potential to extend 
the diagnostic process. This accords with research pointing to the cre-
ation and exacerbation of uncertainty resulting from novel genomic 
techniques (Kerr et al., 2019; Skinner et al., 2016; Timmermans et al., 
2017). In some cases, participants returned to clinical judgement to 
interpret the implications of their gene expression test result for treat-
ment. This was not only in the case of an intermediate score, a ‘zone of 
uncertainty’ where clinical judgement is more often called upon 
(Bourgain et al., 2020), but also observed in cases where a recom-
mended course of action was clearly inscribed within the result. Patient 
deferral to their clinician points to a “persistence of the clinic” (Latimer 
et al., 2006: 623), despite suggestions that genomic technologies would 
relegate clinical judgement. In such cases, clinicians weaved together 
sometimes contradictory diagnostic layers, patient priorities, concerns 
and fears, and professional assessments with this genomic information, 
in order to develop an appropriate treatment recommendation for their 
patient. Of note in this research is that clinical judgement also drew on 
cultural narratives entwining chemotherapy and cancer, and the possi-
bility of future regret. 
The layer of diagnostic information provided by Oncotype DX, 
despite often being represented as advanced, and experienced as such by 
some patients, in fact shared many characteristics with that provided by 
established tools. Due to its conflation of diagnostic and prognostic in-
formation, like previous diagnostic layers the Oncotype DX result could 
contradict established configurations of patients’ cancers, causing 
confusion and anxiety. Our analysis has shown that despite its purported 
exceptionalism, the result was not interpreted in isolation by patients, 
but made sense of in light of previous diagnostic results. Their signifi-
cance was not reconfigured by the technique. Further, like previous 
layers the Oncotype DX score remained open to contestation and re- 
interpretation, with some participants embarking upon further 
discussions with their clinician about its meaning, even in apparently 
clear-cut cases. Lastly, though marked as distinct by some interviewees 
for providing ‘scientific facts’ on which to base a treatment decision, 
interpretations of the test result remained couched within persistent 
fears of cancer and its possible return. These influenced the way all 
participants engaged with Oncotype DX, provoking strong emotional 
engagement with results, whether these indicated chemotherapy or not. 
6. Conclusion 
Our research has attended to routinized and everyday practices of 
breast cancer diagnosis in the UK, into which molecular examination has 
been embedded for many years. We have contributed to the sociology of 
diagnosis by attending in-depth to how contemporary techniques that 
‘split’ breast cancer into subtypes are experienced by patients. Our 
analysis has demonstrated that multiple laboratory examinations of 
tumour tissue extend diagnosis for patients, and introduce more op-
portunities for the invalidation of women’s anticipations for their 
treatment and care. The concept of diagnostic layering, directly devel-
oped from patient accounts, captures these experiences of contemporary 
breast cancer diagnosis as partial and incomplete, and as mutable and 
subject to change. 
As a relatively recent introduction to routine diagnostic processes, 
Oncotype DX could be represented as a ‘final’ diagnostic layer, due to its 
ability to determine treatment where previous techniques had failed. 
Patients anticipated that the technique would resolve treatment un-
certainties provoked by established diagnostic tools, and in some cases 
take the heavy responsibility for treatment decision-making out of their 
hands. We have shown that for some patients this was the case, with 
these women attributing their “confidence” in this genomic test to its 
“advanced” nature, and its provision of a direct recommendation for 
treatment. However, our analysis has also highlighted that the result did 
not straightforwardly direct treatment decisions for all. Some women 
described the incorporation of the result into their decision-making as 
informed by diagnostic information arising from well-established tools, 
which could entail contradictions, and as powerfully shaped by fears of 
cancer and its return. This led several participants to interrogate the 
meaning of the result further, requiring additional interpretation and 
disrupting anticipations for the finalisation of diagnostic and treatment 
pathways. In these cases the enduring significance of the clinician in 
interpreting genomic information, and translating this into a treatment 
recommendation for the individual patient, was clear. 
In line with personalised medicine’s aim to further refine diagnosis 
and treatment, it is likely that additional layers of diagnostic informa-
tion derived from novel genomic techniques will become incorporated 
into routine cancer care. However, scientists now highlight the diversity 
of breast cancer even within individual patients, and as shifting over 
time (Martelotto et al., 2014). This calls into question the extent to 
which the much sought after ‘finality’ in cancer diagnosis can be ach-
ieved, with layering perhaps better understood as a process continuing 
even beyond treatment. Our article has highlighted the importance of 
sociological attention to the specificities and temporality of diagnostic 
layers; how they are produced and in what contexts, and of the lived 
consequences of these diverse forms of clinical information for patients. 
Our analysis of patient accounts of Oncotype DX has shown that patients 
make sense of novel forms of diagnostic information in terms of the 
techniques that have produced it, the extent to which it aligns with other 
sources of diagnostic information, and in the context of wider disease 
experiences. Such insights are important for medical practice, as pa-
tients face navigating further layers of complex diagnostic information, 
and as clinicians manage patient (as well as their own) expectations for 
genomic techniques to resolve diagnostic uncertainties (Kerr et al., 
2019). 
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